NEW YORK and TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, today reported its financial results for the third quarter ended September 30, 2025. The Company’s Quarterly Report on Form 10-Q (the “Quarterly Report”), which includes its unaudited interim condensed consolidated financial statements for the three and nine months ended Se ...

Third quarter results reflect temporary planned scaled back in new planting and wholesale productionCompany remains on track to return to full production at existing greenhouses in the first quarter of 2026, by year-end 2025 will have the most cannabis acreage planted in the Company’s historyPreviously announced $95 per pound of biomass full year production cost target remains intactConference Call to be held today November 12, 2025 at 5:00 p.m. ET LONG BEACH, Calif. and TORONTO, Nov. 12, 2025 (GLOBE NEWSWI ...

Core Insights - Canopy Growth (CGC) reported Q2-2026 financial results showing higher revenues year-over-year and an improved net loss [1] - The company has paid down some of its debt and increased its cash positions [1] Financial Performance - The company experienced an increase in revenues compared to the previous year [1] - There was a notable improvement in net loss figures, indicating better financial health [1] Debt and Cash Management - Canopy Growth has successfully reduced its debt levels [1] - The company has also enhanced its cash reserves, which may provide more operational flexibility [1]

Core Insights - Canopy Growth (CGC) reported Q2-2026 financial results showing higher revenues year-over-year and an improved net loss [1] - The company has paid down some of its debt and increased its cash positions [1] Financial Performance - The company experienced a year-over-year increase in revenues [1] - There was an improvement in net loss compared to previous periods [1] - Debt reduction and an increase in cash positions indicate a strengthening financial position [1]

Core Insights - EnWave Corporation has signed a royalty-bearing commercial license agreement with Shinyway International Limited for the use of its Radiant Energy Vacuum (REV™) technology in cannabis product production in New Zealand [1][2]. Company Overview - EnWave is a leader in vacuum microwave dehydration technology, with a strong intellectual property portfolio and a focus on providing efficient drying solutions for the food, pharmaceutical, and cannabis industries [4]. - The company has over fifty partners across twenty-four countries, enabling them to create innovative snacks and ingredients while improving product quality and market efficiency [5]. Shinyway International Limited - Shinyway specializes in drying and trimming services for cannabis growers in New Zealand and plans to install a 10kW REV™ machine to enhance its competitive edge [3]. - The company aims to build collaborative relationships with local growers and is committed to supporting the growth of New Zealand's cannabis industry through responsible practices and innovation [3]. Technology and Benefits - EnWave's REV™ technology allows for faster and more economical drying compared to traditional methods, improving product taste, texture, color, and nutritional value [6]. - The technology enables producers to reach optimal moisture levels up to seven times faster than conventional drying methods [6].

Core Insights - Bespoke Extracts, Inc. reported record results for Q3 2025, achieving its strongest operational and financial performance to date [1] - The company emphasizes disciplined execution and brand trust as key factors for success in a contracting cannabis market [2][3] Financial Performance - Revenue for Q3 2025 reached $467,945, representing a 68.6% increase year-over-year and a 19.8% increase from Q2 2025 [4][6] - Gross profit was $234,175, up 103.6% from Q3 2024, with a gross margin of 50.0%, an increase of 860 basis points year-over-year [4][6] - Operating expenses decreased by 23.7% compared to Q3 2024, leading to a net loss of $78,088, a 71.7% improvement from the previous year [4][6] Production and Market Strategy - The company produced 209,600 pre-rolls in Q3 2025, an 81% increase year-over-year [6] - Bespoke Extracts aims to replicate its successful model across additional regulated markets, including Massachusetts and New York [10] Future Outlook - Projected revenue for Q4 2025 is between $425,000 and $500,000, indicating a year-over-year growth of 41% to 66% [10] - The company plans to launch two new brands in Q4 to capture adjacent market segments [10]

Core Insights - Charlotte's Web Holdings, Inc. reported a strategic transformation in Q3 2025, focusing on operational improvements and product innovation to enhance performance in 2026 [2][4][21] - The company has launched a Scientific Advisory Board to support its medical channel strategy and reinforce its commitment to science-backed innovation [5][6] - A restructuring of the B2B retail operations was implemented to adapt to regulatory changes, prioritizing high-margin channels and reducing lower-margin sales [7][19] Financial Performance - Q3 2025 revenue was $11.5 million, an 8.6% decrease from $12.6 million in Q3 2024, primarily due to a strategic shift in the B2B business model [17][20] - Gross profit for Q3 2025 was $4.5 million, representing a gross margin of 38.9%, down from 53.0% in Q3 2024, affected by a one-time chargeback reserve and higher costs during the transition to in-house manufacturing [18][20] - SG&A expenses decreased by 23.3% year-over-year to $9.7 million, reflecting effective cost management strategies [19] Operational Improvements - The company achieved full internalization of Brightside™ gummy production, enhancing manufacturing capacity and cost absorption [3][4] - Additional expense reductions are expected to yield approximately $9 million in annualized savings in 2026, supporting a path toward positive cash flow [4][21] - The transition to in-house manufacturing is anticipated to improve gross margins as production scales, targeting approximately 75% of total gummy sales volume over time [18] Product Innovation - Charlotte's Web expanded its sleep product portfolio, with the CBN Stay Sleep Gummies becoming the second-best-selling gummy product [2][9] - The introduction of Brightside™ hemp-derived delta-9 products has shown promising early performance, indicating strong market demand [2][11] - The company is entering the nootropics segment with CBG Focus & Attention Gummies, diversifying its product offerings beyond traditional CBD [9] Regulatory and Industry Context - Recent federal legislative developments have introduced uncertainty, but the company remains optimistic about achieving a balanced regulatory framework for CBD wellness products [10][11] - The company is actively engaging with bipartisan Congressional champions and industry coalitions to support favorable regulatory outcomes [11][12] - State-level restrictions have prompted a restructuring of the B2B distribution strategy, focusing on high-margin accounts to improve long-term profitability [11][12] Strategic Partnerships - Charlotte's Web is collaborating with DeFloria, Inc. for FDA Phase 2 clinical trials of a botanical drug aimed at treating irritability associated with autism spectrum disorder, representing a potential long-term revenue opportunity [12][15] - The partnership with Ajna BioSciences and British American Tobacco highlights the company's leadership in advancing hemp-derived compounds into FDA-regulated pharmaceutical development [12][15]

Core Insights - Cresco Labs has launched its flagship flower brand in Germany, marking its first entry into the European Union cannabis market [1][2] - The launch is part of Cresco's growth strategy to expand beyond the U.S. cannabis market and gather insights for future international expansion [2][3] Company Strategy - The company aims to leverage its portfolio of market-leading brands and operational capabilities to create value in the European market [3] - Cresco Labs is collaborating with Blossom, its EU GMP-certified manufacturing partner in Portugal, to introduce three signature flower products tailored to specific patient effects [3] Market Context - Germany is recognized as one of the fastest-growing regulated cannabis markets globally, supported by a robust regulatory framework and an increasing patient base [2] - The launch of Cresco products is available via prescription through licensed pharmacies across Germany, indicating a structured approach to market entry [4]

Core Insights - Village Farms (VFF) reported strong financial performance for Q3-2025, with increasing revenue, net income, and free cash flow, driven by international sales [1] - Profit margins have also increased significantly, contributing to the overall positive financial results [1] - The stock price of Village Farms has surged by 378.85% over the last year, indicating strong market performance [1] Financial Performance - Revenue, net income, and free cash flow have all shown an upward trend in Q3-2025 [1] - The increase in profit margins reflects improved operational efficiency and cost management [1] - International sales are a key driver of the revenue growth, highlighting the company's expanding market reach [1]

Core Viewpoint - The potential reclassification of marijuana from Schedule I to Schedule III by the Trump administration could significantly impact the cannabis industry, unlocking new investment opportunities and tax benefits while also facilitating research on marijuana [4][5][22]. Group 1: Economic Impact - Reclassification could lead to billions in untapped potential in the hemp industry, positively affecting the U.S. economy and stock market [4]. - Cannabis businesses would gain access to major tax breaks, allowing them to deduct normal business expenses, which could result in significant tax savings [3]. - The reclassification may help normalize the cannabis industry in the eyes of mainstream investors, potentially increasing investment interest [2][12]. Group 2: Research Opportunities - The change would simplify federally approved research on marijuana, enabling scientists to explore new use cases and markets [2][22]. - Currently, research on Schedule I drugs is highly restricted, limiting the ability of companies to innovate within the cannabis sector [2][6]. Group 3: Market Sentiment and Trends - Support for cannabis legalization has grown, with approximately 64% of Americans favoring legalization, although this is a slight decrease from 68% in 2024 [11]. - The cannabis industry is characterized by volatility, with stocks often experiencing significant price swings in response to policy news [13][22]. Group 4: Investment Considerations - Investors should carefully consider their exposure level, as different types of cannabis stocks (growers, dispensaries, ETFs, pharmaceutical companies) come with varying risk and growth potential [18]. - The cannabis industry remains emerging and risky, with the timeline for federal legalization or banking reform still uncertain [22].